Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Invested Capital: 2019-2025

Historic Invested Capital for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to $946.3 million.

  • Kymera Therapeutics' Invested Capital rose 5.97% to $946.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $946.3 million, marking a year-over-year increase of 5.97%. This contributed to the annual value of $835.6 million for FY2024, which is 111.56% up from last year.
  • As of Q3 2025, Kymera Therapeutics' Invested Capital stood at $946.3 million, which was down 2.60% from $971.5 million recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Invested Capital high stood at $971.5 million for Q2 2025, and its period low was $258.1 million during Q2 2021.
  • Moreover, its 3-year median value for Invested Capital was $711.2 million (2024), whereas its average is $683.3 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Invested Capital soared by 393.43% in 2021, and later decreased by 22.88% in 2023.
  • Over the past 5 years, Kymera Therapeutics' Invested Capital (Quarterly) stood at $459.6 million in 2021, then rose by 6.64% to $490.2 million in 2022, then fell by 19.42% to $395.0 million in 2023, then skyrocketed by 111.56% to $835.6 million in 2024, then rose by 5.97% to $946.3 million in 2025.
  • Its Invested Capital stands at $946.3 million for Q3 2025, versus $971.5 million for Q2 2025 and $786.2 million for Q1 2025.